aibioNAUT Nautilus Biotechnology, Inc.
Nautilus Biotechnology (NAUT) news
Nautilus Biotechnology, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker NAUT, recorded under United States. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.
Latest Nautilus Biotechnology news
We have not published a story on Nautilus Biotechnology yet. When there is news, it will appear here.
Nautilus Biotechnology annual financials
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $41.1 million | $50.5 million |
| Net income (loss) | -$59.0 million | -$70.8 million |
| Cash from operations | -$50.7 million | -$59.1 million |
| Cash and equivalents | $12.4 million | $27.6 million |
| Short-term investments | $91.0 million | $102.2 million |
Questions about Nautilus Biotechnology
What is the ticker symbol of Nautilus Biotechnology?
Nautilus Biotechnology, Inc. trades under the ticker NAUT on NASDAQ.
Where is Nautilus Biotechnology listed?
Nautilus Biotechnology, Inc. is listed on NASDAQ.
Which country or territory is Nautilus Biotechnology listed under?
Our directory records Nautilus Biotechnology, Inc. under United States.
Does aibio.space cover Nautilus Biotechnology?
aibio.space lists Nautilus Biotechnology, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
Is Nautilus Biotechnology profitable?
Nautilus Biotechnology, Inc. reported a net loss of $59.0 million for the fiscal year ended Dec 31, 2025, and used $50.7 million of cash in operations, per its annual report to the SEC.
How much does Nautilus Biotechnology spend on research and development?
$41.1 million in the fiscal year ended Dec 31, 2025, per its annual report.
How much cash does Nautilus Biotechnology have?
$86.6 million in cash and short-term investments at Sep 30, 2026, per its 10-Q.
Investor discussion: Nautilus Biotechnology
Rules
- Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
- Say whether you hold the stock. Every post states long, short or no position.
- No paid or sponsored posts. Do not post for anyone who pays or rewards you.
- No buy or sell calls and no price targets.
- No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
- No personal details and no spam. No links at all for your first 7 days as a member.
Capital-markets timeline
- Financings
Reported a financing. SEC Form 8-K (Items 1.01,1.02,9.01). Source
Stock chart
Listing details
- Company
- Nautilus Biotechnology, Inc.
- Ticker
- NAUT
- Listing
- NASDAQ
- Country or territory
- United States
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction